NASDAQ: ATHE - Alterity Therapeutics Limited

Rentabilidade por seis meses: +73%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Alterity Therapeutics Limited

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

mais detalhes
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 1.45
Alteração de preço por dia: -0.2858% (3.149)
Alteração de preço por semana: +42.73% (2.2)
Alteração de preço por mês: +188.07% (1.09)
Alteração de preço em 3 meses: +136.98% (1.325)
Mudança de preço em seis meses: +73% (1.815)
Mudança de preço por ano: +26.1% (2.49)
Mudança de preço em 3 anos: +256.01% (0.882)
Mudança de preço em 5 anos: +204.85% (1.03)
Mudança de preço em 10 anos: 0% (3.14)
Mudança de preço desde o início do ano: +193.46% (1.07)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 4.09 4
P/BV 1.19 9
P/E 0 0
EV/EBITDA -0.2025 0
Total: 5.38

Eficiência

Nome Significado Nota
ROA, % -82.18 0
ROE, % -104.47 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0081 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 876.58 10
Rentabilidade Ebitda, % 89.99 9
Rentabilidade EPS, % 31034.18 10
Total: 8.6
Mais detalhes

Instituições Volume Compartilhar, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



Supervisor Cargo Pagamento Ano de nascimento
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 anos)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 ano)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 anos)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 anos)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Endereço: Australia, Melbourne, 350 Collins Street - abrir no Google Maps, abrir mapas Yandex
Site: https://alteritytherapeutics.com